Mr. Amin: AmexDrug Corporation is actually a vertically integrated pharmaceutical and cosmeceutical manufacturing company. We have subsidiaries, such as BioRX Pharmaceuticals, Allied Medical Wholesale, Dermagen, Inc., which develop, manufacture, market and distribute pharmaceutical and innovative skin care products within the United States.
TWST: Please explain the makeup of your customer base and who your direct competition is today.
Mr. Amin: Basically, our customer base are independent pharmacies, wholesalers and chain drug stores. Within a year, we're planning to distribute our product, which is trademarked as SPONIX within the retail markets such as CVS, Kroger's, Walgreens. We would like to get our products within those stores within next year or so.
TWST: How has the company been managing during this downturn? You're based on the West Coast, is that right?
Mr. Amin: That's correct. We're in Los Angeles, California.
Actually, we're doing very well; we're doing better than last year and the year before. Our sales are going up, according to our last quarter. We had, I believe, a 50% to 60% jump on our revenue, and this quarter we're going to have another jump. We're working against the downturn. So we're going up, our sales are going up, our margin is going up and we have added prescription packaging products to our line as well. We have had more distribution to stores, to independent pharmacies nationwide as we're picking up a few smaller chain drug stores. So we've been doing pretty well.
Tickers included in this excerpt: AXRX.OB
For more information call (212) 952 7433. The Wall Street Transcript does not endorse any of the comments made by interviewees, and does not make stock recommendations.